Coronavirus spike (S) glycoprotein trimers promote entry into cells and are the main targets of the humoral immune response. We demonstrated that ACE2 is a functional entry receptor for this novel coronavirus and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans. We determined cryo-electron microscopy structures of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry. SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination. We subsequently isolated a monoclonal antibody from the memory B cells of an individual who was infected with SARS-CoV in 2003 and show that it potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 . Our results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
Please click this link to join the webinar.
Or iPhone one-tap :
US: +16507249799,,93908153080#,,1#,351530# or +18333021536,,93908153080#,,1#,351530# (Toll Free)
Dial (for higher quality, dial a number based on your current location):
US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 939 0815 3080
International numbers available: https://stanford.zoom.us/u/aAkZfXvG1